Antimicrobial resistance analysis of clinical Escherichia coli

Sammendrag

Introduction. Antibiotic resistance (AMR) is a major public health challenge when it comes to tackling infectious diseases. The Pasteur Institute identified AMR as a priority scientific area in its Strategic Plan for. According to the World Health Organization, Geneva, Switzerland, antibiotic resistance is rising to dangerously high levels in all parts of the world, leading to increased morbidity and mortality. Hence, the six leading mortality-causing pathogens - Escherichia coli, Staphylococcus aureus, Klebsiella pneumonia, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa - were responsible for 929.000 deaths linked to AMR and 3.57 million deaths associated with AMR in 2019. E. coli is the most common gram-negative bacterium responsible for a variety of diseases as a result of community and hospital-acquired clinically significant bloodstream infections, and causes a major number of deaths at all ages, due to these infections.

The aim of this study was to analyze antibiotic resistance and detect some antimicrobial resistance genes in E. coli strains.

Material and methods. This cross-sectional study was conducted between February 2020 and January 2022. The identification of E. coli isolates was done by MALDI-TOF MS, VITEK 2 Compact, and AST was performed with the Kirby–Bauer disk diffusion and VITEK 2 Compact. Extended-spectrum β-lactamases (ESBLs) were detected with discs containing cefotaxime, cefotaxime/clavulanate, ceftazidime, and ceftazidime/clavulanate, and carbapenemase was detected with the modified carbapenem inactivation method (mCIM) and EDTA-mCIM (eCIM). Antibiotic resistance genes were identified by polymerase chain reaction.

Results. The study aimed to investigate the antibiotic resistance patterns of, E. coli strains isolated from blood, cerebrospinal fluid and urine. Phenotypic analysis by the disk diffusion method showed that the E. coli isolates were resistant to penicillin (40.3%), fluoroquinolones (38.1%), cephalosporins (42.1%), and aminoglycosides (16.9%). 39.5% of the E. coli isolates were multi-drug resistant (i.e., resistant to 3 or more classes of antibiotics), and 31.7% of those were positive for extended spectrum β-lactamase. The carbapenemase-producing strains were further evaluated for the presence of resistance genes. It was observed that blaOXA-48 was detected in 4.9% of carbapenemase- produsing isolates, while blaNDM was detected in 2.9% of the same group.

Conclusions. Drug-resistant E. coli has become an important and complex problem in clinical treatment. This work reports a high rate of antimicrobial resistance, including ESBL positivity and multidrug resistance. The data reported here are highly relevant for local antimicrobial prescription practice. In the future, this research can be expanded to increase sample size and the type and to enable evaluation of the correlation between clinical manifestations and antibiotic resistance. This newly available information about E. coli resistance will help improving clinical evaluation and decision-making.

Notă: This paper has been written within the framework of the project: 20.80009.8007.09 "Studying the mechanisms of antimicrobial resistance in gram-negative bacilli in order to strengthen the national surveillance system"n-making.

pdf (English)

|Utsikt: 115| |pdf (English) Nedlastinger: 44|


pdf (English)
##submission.license.cc.by4.footer##

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

ANNOUNCEMENT

Starting from July 1, 2025, the article processing fee will be 20 EUR (or the equivalent in MDL at the official exchange rate of the National Bank of Moldova). The publication fee for an accepted article will be 150 EUR (or the equivalent in MDL).

Details here:

Processing Fee
A processing fee of 20 EUR (or the equivalent in MDL) will be charged for articles accepted for scientific review by the editorial committee of the One Health and Risk Management journal.
Note: This fee will only be charged if your article has been technically reviewed and accepted.

Publication Fee
Starting from 01.07.2025, a fee of 150 EUR (or the equivalent in MDL) will be charged for articles accepted for publication.
Additionally, authors will bear the cost of English language editing/translation services if the manuscript requires intervention. The fee is 5 EUR (or the equivalent in MDL) per page edited/translated.
The total cost for English editing/translation services will be communicated by the Editorial Board after the manuscript is accepted for publication.

Payment Details:
Payments should be made in MDL to the bank account opened in the name of the Biosafety and Biosecurity Association of the Republic of Moldova.
The invoice will be issued by the end of the month in which the payment was made.

Organization: Biosafety and Biosecurity Association of the Republic of Moldova
Address: 5C A. Cozmescu Street
Fiscal Code: 1017620004120
Bank Code (SWIFT): AGRNMD2X451
IBAN: MD34AG000000022513622370